Prof. Parimal Misra
Senior Professor & Chief Scientist
Prof (Dr.) Parimal Misra is Senior Professor and Chief Scientist, Center for Innovation in Molecular and Pharmaceutical Sciences, Dr. Reddy’s Institute of Life Sciences, Hyderabad. He has done his Bachelors in Chemistry (Hons) and MSc in Molecular Biology from Kolkata University. He has done his PhD in Indian Institute of Chemical Biology, Kolkata, India in the area of molecular biology and biochemistry and was awarded PhD degree from Jadavpur University, Kolkata in 1995. He has done his Post-Doc in Institute of Microbial Technology, Chandigarh on TB from 1995-96. He was a visiting scientist of the Feinberg School of Medicine, Northwestern University, Chicago in the Dept. of Pathology. He worked in the area of transcriptional complex, co-factors, gene-regulation and signal transduction of various transcription factors related to stress induced diabetes and insulin resistance. Dr. Misra worked in Dr. Reddy’s and Dr. Reddy’s Institute of Life Sciences for more than 27 years in the areas of Metabolic Disorder, Inflammation, tuberculosis and Genomics-Proteomics. He has published 59 articles in scientific journals authored four book chapters and published 12 international and 15 national patents. He has been awarded numerous grants from DBT, DBT-Center of Excellence, DST and a collaborative RO1 grant for NIH-USA with Prof. Janardan K Reddy, Former Chairman, Dept. of Pathology, Northwestern University, Chicago. He has been elected as a Fellow of the Royal Society of Chemistry (UK) in 2016 and Fellow of the Royal Society of Biology (UK) in 2017. Dr. Misra got highly prestigious Chairman Excellence Award from Dr. K. Anji Reddy in 2004 and awarded International Young scientist travel award in Molecular Biology in 1994 by IUBMB (International Union of Biochemistry and Molecular Biology) and a member of the National Committee for International Union of Physiological Sciences (IUPS) and International Union of Pharmacology (IUPHAR), January 1, 2024 – December 31, 2026.
Prof. Misra worked with the PPAR and AMPK targets in the therapeutic area of diabetes and obesity in Dr. Reddy’s and DRILS, Hyderabad and 1) contributed to put five NCEs in different clinical phases including Balaglitazone- Partial PPARγ agonist (Phase3B), Ragaglitazar-1st in class PPARα and γ dual activator (Phase3A), DRL10945-PPARα agonist (Phase2A), DRL11605-Pan PPAR and DRL16536, a 1st in class AMPK activator (Phase1) and an excellent anti-obesity NCE. 2) His group has identified PRIP-interacting protein with methyl transferase domain (PMIT) as a new player in stress-induced Type 2 diabetes (T2D) and stated that ablation of PIMT promotes nuclear translocation of insulin in the pancreatic β-cells and inhibition of PIMT leads to insulin sensitization and body weight loss and 3) contributed to describe a new mechanism of how statins, the widely used cholesterol-lowering drugs, may cause insulin resistance and diabetes by increased fatty acid accumulation within the muscle cells thus impairing insulin signaling and they further showed that statins enhance the diabetes in the hyperglycemic, hyperlipidemic and obese animals and 4) contributed to discover the 1st in class small molecule inhibitor of Chorismate Mutase (CM) and establishment of proof of concept in animal for the treatment of latent, replicating and MDR TB.